



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Leucylarginylproline

Cat. No.:	HY-P0143
CAS No.:	133943-59-6
Molecular Formula:	C <sub>17</sub> H <sub>32</sub> N <sub>6</sub> O <sub>4</sub>
Molecular Weight:	384.47
Sequence:	Leu-Arg-Pro
Sequence Shortening:	LRP
Target:	Angiotensin-converting Enzyme (ACE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Leucylarginylproline is an angiotensin-converting enzyme (ACE) inhibitor with an IC <sub>50</sub> of 0.27μM.
IC <sub>50</sub> & Target	IC <sub>50</sub> : 0.27μM (ACE) <sup>[1]</sup>
In Vitro	Intravenous injection of Leucylarginylproline (30mg/kg) causes a decrease in the blood pressure. The maximum mean blood pressure reduction (about 15 mmHg) occurs about 2 min after the injection <sup>[1]</sup> . Leucylarginylproline peptide reduces the blood pressure by about 15 mmHg at the fourth hour and shows a maximal reduction effect of about 35 mmHg at the eighth hour after oral administration <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### PROTOCOL

Kinase Assay <sup>[1]</sup>	Hip-His-Leu (5mM) and an ACE inhibitor (Leucylarginylproline) are dissolved in a 100 mM sodium borate buffer (pH 8.3) containing 300 mM NaCl, and incubated for 30 min with 8 milliunits of ACE at 37°C. The ACE inhibitor concentration required to inhibit 50% of the ACE activity under the above conditions is defined as IC <sub>50</sub> <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration <sup>[2]</sup>	Rats: Leucylarginylproline is dissolved in 1.0 mM normal saline. After being warmed up, rats are orally administered (0.18 mmol/kg bw) with peptides or normal saline (control). Tail systolic blood pressures are measured at 2-h intervals (0, 2, 4, 6, 8, 10, and 12 h) after the administration <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Miyoshi S, et al. Structures and activity of angiotensin-converting enzyme inhibitors in an alpha-zein hydrolysate. Agric Biol Chem. 1991 May;55(5):1313-8.
- [2]. Chen TL, et al. Microencapsulation and modification of synthetic peptides of food proteins reduces the blood pressure of spontaneously hypertensive rats. J Agric Food

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA